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Abstract
Methods We applied multiparametric MRI to assess changes in liver composition, perfusion and blood flow in 17 patients before
direct-acting antiviral (DAA) therapy and after treatment completion (within 12 weeks of last DAA tablet swallowed).
Results We observed changes in hepatic composition indicated by a reduction in both liver longitudinal relaxation time (T1, 35 ±
4 ms), transverse relaxation time (T2, 2.5 ± 0.8 ms; T2* 3.0 ± 0.7 ms), and liver perfusion (28.1 ± 19.7 ml/100 g/min) which we
suggest are linked to reduced pro-inflammatory milieu, including interstitial oedema, within the liver. No changes were observed
in liver or spleen blood flow, splenic perfusion, or superior mesenteric artery blood flow.
Conclusion For the first time, our study has shown that treatment of HCV with DAAs in patients with cirrhosis leads to an
acute reduction in liver T1, T2 and T2* and an increase in liver perfusion measured using MR parameters. The ability of
MRI to characterise changes in the angio-architecture of patients with cirrhosis after intervention in the short term will
enhance our understanding of the natural history of regression of liver disease and potentially influence clinical decision
algorithms.
Key Points
•DAAs have revolutionised the treatment of hepatitis C and achieve sustained virological response in over 95% of patients, even
with liver cirrhosis.
• Currently available non-invasive measures of liver fibrosis are not accurate after HCV treatment with DAAs, this prospective
single-centre study has shown that MRI can sensitively measure changes within the liver, which could reflect the reduction in
inflammation with viral clearance.
• The ability of MRI to characterise changes in structural and haemodynamic MRI measures in the liver after intervention will
enhance our understanding of the progression/regression of liver disease and could potentially influence clinical decision
algorithms.
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Abbreviations
DAAs Direct-acting antiviral treatments
HCV Hepatitis C virus
HVPG Hepatic venous portal gradient
NHS National Health Service
SVR Sustained virological response
Introduction
Globally, chronic hepatitis C virus (HCV) infection is estimat-
ed to affect 71 million people [1]. Direct-acting antivirals
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(DAAs) have revolutionised HCV treatment, with sustained
virological response (SVR) rates approaching 100% in com-
pensated cirrhosis [2–4], emerging data suggesting excellent
SVR in decompensated liver disease [5, 6]. Despite high SVR
rates, there is an incomplete understanding of the effect of viral
clearance on the liver in the context of DAA therapy. The
progression or regression of fibrosis and/or portal hypertension
caused by DAA therapy could have implications for each pa-
tient wider than chronic HCV management alone. Potential
changes include those reflecting liver composition, including
volume, inflammation and fibrosis; and hepatosplanchnic hae-
modynamic changes, including liver perfusion and blood flow.
Improvement in clinical outcomes following HCV eradica-
tion with treatment regimens of pegylated interferon and riba-
virin is established; large cohort studies show differences in
liver decompensation rates between SVR and non-SVR
groups: hazard ratio (HR) 0.24 (95% CI 0.14–0.42), p < 0.001
[7]; HR 0.26 (95% CI 0.17–0.39), p < 0.001 [8]; and HR 0.15
(95%CI 0.06–0.38), p = 0.04 [9]. Assessment by invasive liver
biopsy in HCV patients with established cirrhosis has shown
regression of cirrhosis in 61% and reduction of collagen in 89%
of patients at 61 months following an SVR [10]. Further studies
using liver biopsy have shown cirrhosis regression rates of 46
to 75% after 3–10 years [11–14]. Although promising, regres-
sion was not ubiquitous nor studied in those with the most
advanced liver disease due to the known risks of treatment with
interferon and ribavirin. It remains unproven whether the re-
gression seen was due to selection bias of those who achieved
SVR, aviraemia or an immunomodulatory effect of the inter-
feron itself [15]. Hepatic venous pressure gradient (HVPG), an
invasive measure of portal hypertension, also improves with
SVR [16–18]. Together, this published data builds a strong case
for the concept of regression.
However, individual and invasive techniques for measur-
ing fibrosis and portal hypertension respectively do not assess
the complex pathophysiological changes associated with pro-
gression and regression of chronic liver injury. Furthermore,
ethical and practical constraints limit serial liver biopsy sam-
pling with DAA therapy. A multicentre prospective study,
with paired invasive HVPG and non-invasive transient
elastography (TE), demonstrated DAA therapy significantly
reduced HVPG, but patients continued to have clinically sig-
nificant portal hypertension and remained at risk of decom-
pensation [19]. Currently available clinical non-invasive
markers, including TE, overestimate regression compared to
biopsy after SVR [19, 20]. In an era of novel antifibrotic
therapy on the horizon, robust non-invasive biomarkers for
use in advanced liver disease patients who receive DAA ther-
apy to understand the structural and functional changes in the
liver and stratify ongoing risk post SVR and focus interven-
tions are required.
Non-invasive, contrast agent-free, quantitative
multiparametric magnetic resonance imaging (MRI) provides
the opportunity to assess liver composition (volume, fibrosis/
inflammation) and haemodynamics (liver tissue perfusion,
blood flow) in a single scan session (< 40 min). Longitudinal
relaxation time (T1) of liver tissue is validated against
inflammation/fibrosis on liver biopsy [21–23], and MRI mea-
surements also closely correlate with the invasive HVPGmea-
surement [24]. Inflammation lengthens hepatic transverse re-
laxation time (T2) in liver disease [25–27]. More recently,
specific MR liver biomarkers, including liver T1 and liver
perfusion, predicted clinical outcomes [28, 29].
Here, we collect quantitative MRI data in patients with
liver cirrhosis who underwent DAA therapy from the NHS
England expanded access programme [5]. This study de-
scribes the early changes in structural and haemodynamic
MRI measures in the liver between baseline (pre-treatment)
and follow-up to SVR (immediately post-treatment) at a 3–6-
month time window following the start of DAA therapy, in
patients with advanced end-stage liver disease.
Methods
In this prospective, observational study, patients were recruit-
ed through the NHS England expanded access programme,
established to prioritise treatment for patients with greatest
clinical priority, including compensated and decompensated
liver disease. Treatment was with sofosbuvir plus, by clinician
choice, ledipasvir or daclatasvir, with or without ribavirin [5,
30]. The study received ethical approval from the NRES
Committee East Midlands - Derby 1 (Research Ethics
Committee reference 11/EM/0314). Once enrolled in the
study, if a subject did not attend a study visit after treatment,
they were sent a letter and telephoned twice by the research
team and withdrawn from the study if uncontactable.
Patients underwent a detailed MRI study before DAA ther-
apy and after treatment completion (within 12 weeks of last
DAA tablet swallowed). Patients followed standard manage-
ment protocols for DAA therapy and monitoring. Routine
clinical information including medical history, clinical exam-
ination and laboratory values were recorded for each partici-
pant. Laboratory values were used to calculate validated
scores of ALT, Fib4 [25] and APRI [26] using freely available
online calculators.
MRI measures
MRI data were acquired on a 1.5-T Philips Achieva scanner
(Philips Healthcare Systems) in a single 40-min scan session
using methods described in [21]. Subjects were scanned feet
first supine after an overnight fast, using a body transmit and
16-element SENSEXL torso coil. The MRI protocol com-
prised a series of non-invasive measures to assess liver
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composition and haemodynamics. Multislice balanced fast
field echo (bFFE) images were initially acquired in three or-
thogonal planes (35 slices of 1.75 × 1.75 × 7 mm3 resolution,
single breath holds per orientation) to locate the liver and
vessels of interest and to estimate liver volume.
Liver composition
Liver T1, T2 and T2* were mapped in nine axial slices through
the liver (field of view (FOV) 288 × 288 mm2, voxel size 3 ×
3 × 8 mm3, 4-mm slice spacing). A modified respiratory-gated
inversion recovery sequence with a fat-suppressed spin echo
echo-planar imaging (SE-EPI) readout scheme was used to
measure liver T1 [22, 27, 28] (inversion times for first SE-EPI
image slice were 100–1000 ms in 100-ms increments). For all
inversion times, SE-EPI imaging slices were collected at end
expiration such that the first slice was collected at 1500 ms after
the respiratory trigger with subsequent slices collected with a
65-ms temporal slice spacing. The T1 mapping sequence was
acquired with slices collected in ascend and descend slice or-
dering to increase the dynamic range of inversion times. In total,
20 inversion times were acquired in < 3 min. A respiratory-
gated SE-EPI sequence was used to map liver T2 comprising
six echo times (TE = 27, 35, 42, 50, 60, 70ms) in approximately
2 min. T2* mapping was collected using a multiecho fast field
echo (mFFE) sequence comprising 12 echo times (TE1 = 5 ms,
ΔTE = 2.5 ms) acquired in a ~ 17-s breath hold. T2 and T2*
datasets were geometrically matched to the T1 dataset.
In-house software was used to create T1, T2 and T2* maps
(MATLAB, The MathWorks Inc.). Prior to data fitting, images
affected bymotion (due tomissing the respiratory trigger) were
discarded. To create T1 and M0 maps, data at the 20 inversion
times were fit using a voxel-by-voxel two-parameter fit. For T2
and T2* mapping, a voxel-by-voxel log-linear least-squares
method was used to fit the echo intensities to create T2 and
T2* maps. To assess the quantitative T1, T2 and T2* maps, a
region of interest covering the liver was selected and a histo-
gram of values within computed. A Gaussian curve was fitted
to the histogram to determine the mode of the T1, T2 and T2*
distribution within the liver; this procedure excludes regions
where vessels are visible within the liver.
Blood flow
Phase contrast (PC)-MRI assessed blood flow through vessels
in the hepatic circulation (portal vein, hepatic artery) as well as
vessels critically related to portal hypertension (splenic artery,
right renal artery, superior mesenteric artery (SMA)) with re-
constructed voxel size of 1.17 × 1.17 × 6 mm3 [22]. PC-MRI
was performed using a single slice turbo field echo (TFE);
slice was placed perpendicular to each vessel. Fifteen phases
were collected across the cardiac cycle for the portal vein, 20
phases for all other vessels, with velocity encoding in the
portal vein of 50 cm/s, in the hepatic, splenic, renal arteries
100 cm/s, and 140 cm/s in the SMA. Each measurement was
acquired in a single < 20-s breath hold. Using Q-flow software
(Philips Medical Systems), mean artery cross-sectional area
(mm2), mean velocity (cm/s), and hence mean bulk flow
(ml/s) over the cardiac cycle were calculated for each vessel.
Liver perfusion
Respiratory-triggered flow-sensitive alternating inversion re-
covery arterial spin labelling (FAIR-ASL) data (288 ×
288 mm2 field of view, 3 × 3 × 8 mm3 voxel, 3 sagittal slices,
slice gap 5 mm) were collected with a balanced fast field echo
(bFFE) readout in approximately 5 min. A base (M0) equilib-
rium scan and T1 map were also acquired for quantification of
hepatic tissue perfusion using a kinetic model. In-house soft-
ware was used to motion correct the images and perform au-
tomatic outlier rejection of images affected by movement prior
to quantification of tissue perfusion [29].
Statistical analysis
Statistical analysis was performed with GraphPad Prism7
software. Continuous variables are expressed as mean ± stan-
dard deviation for normal data otherwise median (interquartile
range), while categorical variables are reported as number of
patients with (proportion of patients with) the certain
characteristic.
Paired Student’s t test is used for comparisons between pre-
and post-treatments for normally distributed data and
Wilcoxon matched pairs signed-rank test when not normally
distributed. All statistical analysis is Bonferroni corrected for
multiple comparisons.
Repeatability of multiparametric MRI measures
To determine between session repeatability of MRI measures,
the intra-subject coefficient of variation (CoV) (defined as the
standard deviation/mean) of multiparametric MRI measures
was assessed. A subset of ten healthy participants (age 23–
37 years, body mass index 20–26 kg/m2) had three scans, at
least 1 week apart and within 4 weeks, at the same time of day
and after an overnight fast to limit diurnal and dietary variabil-
ity. This healthy participant study was approved by the
University of Nottingham Ethics committee.
Results
Seventeen HCV patients with advanced liver disease
underwent DAA therapy within 1 week of their pre-
treatment MRI scan (Table 1). Patients returned for their
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post-treatment MRI scan at a median of 22 days (3–79 days)
after the last DAA taken. Study demographics are provided in
Table 1. Sixteen of 17 patients (94%) achieved SVR, defined
as undetectable serum viral RNA 12 weeks after treatment
completion. Validated serum clinical liver markers of ALT,
Fib4 and APRI were collected at pre- and post-MRI time
points. The majority of patients had significantly improved
liver function test scores post-treatment compared to pre-
treatment (Fig. 1), with a significant group reduction in ALT,
Fib4 and APRI.
Table 2 shows that all MR volume and relaxometry mea-
sures had a CoV < 5%, and all haemodynamic measures
< 15%, apart from hepatic artery blood flow. There were sig-
nificant changes in the liver microstructure as assessed byMR
relaxation times with DAA therapy, with a significant reduc-
tion in liver T1, T2 and T2* after treatment; however, no
change was observed in splenic T1 (Fig. 2). Figure 3 shows
the example of liver T1, T2 and T2* maps pre- and post-DAA
therapy. No significant differences were observed in liver or
spleen volume. No significant changes were observed in any
blood flow measure (hepatic artery, splenic artery, superior
mesenteric artery or portal vein); however, there was an in-
crease in liver perfusion following DAA therapy (Fig. 4).
Paired perfusion data is presented for n = 9 participants, all
of whom achieved SVR. The remaining subjects had inade-
quate paired data due to insufficient anatomical matching be-
tween visits.
Discussion
Using multiparametric MRI in patients with HCV-related cir-
rhosis pre- and post-DAA therapy, we have demonstrated sig-
nificant changes in the liver composition (T1, T2 and T2*) and
haemodynamics over a short time period following clearance
of HCV infection. We did not observe any changes in bulk
hepatic or splanchnic blood flow in the short time frame be-
tween MRI scans.
To our knowledge, this is the first study to document
changes in MR parameters following DAA therapy. Few pre-
vious studies have assessed the effect of HCV treatment on
MRI measures. One previous study assessed the effect of
HCV treatment (pegylated interferon, ribavirin, telaprevir)
on liver diffusion, demonstrating reduced liver apparent diffu-
sion coefficient suggested to be associated with ultrastructural
changes such as cell necrosis/apoptosis and inflammatory cell
infiltration [31]. A recent study showed a small increase in
liver volume following antiviral treatment, which was larger
Table 1 Pre-treatment characteristics of the 17 hepatitis C virus patients
consented to this study
Demographic table
Variable All patients
Age, mean (SD) 53 (8)
Male (%) 14 (82%)
Transplant (%) 3 (18%)
Cirrhosis (%) 15 (88%)
MELD (IQR) 8 (7–8.25)
Compensated (%) 7 (41%)
Decompensated (%) 8 (47%)
Previous variceal haemorrhage 4 (23%)
Ascites 2 (12%)
Jaundice 2 (12%)
Diabetes (%) 2 (12%)
Body mass index median (IQR) 25.6 kg/m2(24.0–27.9)
HCV genotype
1 (%) 9 (53%)
2 (%) 1 (6%)
3 (%) 7 (41%)
Fig. 1 Liver function test markers of all 17 participants (16 of whom achieved SVR) pre-treatment and post-treatment. aA significant reduction in ALT
of 54 ± 25. b Fib4 reduced by 1.6 ± 0.5.c APRI score showed a significant reduction of 31.0 ± 0.3
Table 2 Coefficient of
variance of MRI
measures
MRI Measure CoV (%)
Liver volume 4.6
Liver T1 1.5
Liver T2 4.3
Liver T2* 3.7
Portal vein flow 13.6
Hepatic artery flow 22.7
Liver perfusion 12
Spleen volume 5.2
Spleen T1 1.8
Splenic artery flow 11
SMA flow 7.6
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in patients with SVR [31], interpreted to indicate liver regen-
eration and/or recovery and reduced fibrotic load of the liver.
The strengths of this current study are the prospective re-
cruitment and phenotyping of the patients. The quantitative
MRI parameters have previously been validated against Bgold
standard^measures including liver biopsy [19, 20] and HVPG
[22]. More recently, specific MR liver biomarkers, including
liver T1, liver perfusion and haemodynamic measures, were
associated with clinical outcomes in independent cohorts of
patients [28, 29]. Liver T1 acquisition and analysis have been
shown to be highly repeatable [19], with an intra-subject CoV
< 1.8% and a low inter- and intra-observer variability with
intra-class correlation coefficient > 0.99 [22]. Here, we dem-
onstrate the intra-subject variability in MR relaxation time is
low, with a CoVof 1.5, 4.3 and 3.7% for liver T1, T2 and T2*
respectively, considerably lower than inter-subject variability.
Capturing data pre- and post-treatment enables direct intra-
individual comparisons, strengthening the validity of the data,
since each subject is their own control. We show that in re-
sponse to DAA therapy, the reduction in T1 is more significant
compared to that of T2 and T2*; this could be attributed to the
smaller CoV. However, there is also variability within the
literature in terms of a T2 change, with pre-clinical models
of liver fibrosis shown to result in an increase as well as de-
crease in T2 [32]. It is hypothesised that increased T2 is related
to hepatic inflammation associated with the development of
fibrosis or the proliferation of small biliary ducts in models of
bile duct ligation [27].
The limitations of this study are the small sample size from
a single UK centre, with some variation in patient disease
Fig. 3 Example axial T1 map, T2
map and T2* map showing the
liver pre- and post-DAA
treatment
Fig. 2 Post-treatment with DAA therapy showed (a) a reduction in liver T1 of 35 ± 4 ms, (b) a reduction in liver T2 of 2.5 ± 0.8 ms and (c) a reduction in
liver T2* by 3 ± 0.7 ms. d–f No significant difference is observed in spleen T1, liver volume or spleen volume between pre- and post-DAA treatments
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severity. Due to practical constraints, we were unable to per-
form parallel invasive assessments of liver biopsy or HVPG.
The timing of the MRI scans in close proximity to drug ther-
apy enabled characterisation of changes at an early time point
in subjects who achieve SVR at a later time point.
The observation that only few specific MR parameters
changed in the study time period is relevant. Notwithstanding
the possibility of type 1 and type 2 errors, the lack of significant
changes in liver bulk blood flow potentially indicates the nat-
ural history of Bregression^. Reversal of fibrotic and vascular
networks, which of course may be incomplete [33], is thought
to occur over years. To date, there is limited data showing
histological changes associated with DAA treatment in HIV
coinfection [34] and post-transplant populations [35], both
demonstrating a significant reduction in necroinflammation
with SVR. It is widely recognised that both TE and serum
markers of fibrosis are influenced by necroinflammation [20,
36–38]. Moreover, short-term studies have shown that TE dy-
namically changes during treatment with DAA therapy, and
long-term studies have shown that both TE and serum fibrosis
markers may overestimate regression in the long term [19, 33].
Pegylated interferon and ribavirin ameliorate portal hyper-
tension in patients with HCV monoinfection [16–18] and
HIV/HCV coinfection [39]. Multiple studies similarly show
that DAA treatment results in statistically significant reduc-
tions in HVPG [19, 34, 40, 41] but interestingly may not alter
clinically significant portal hypertension [19].
We speculate our key findings of reduced liver T1, T2 and
T2* and increased liver perfusion are linked by a reduction in
the pro-inflammatory milieu within the liver, including inter-
stitial oedema, aligned with a reduction in serum ALT. We
hypothesise that DAA treatment reduces necroinflammation
which may improve liver function over a longer period of time
[30] and can be a treatment for portal hypertension provided
treatment in the early stage of portal hypertension [19], and we
believe this also underlies the reported change in TE [20]. A
reduction in necroinflammation on liver biopsy in the short
term, even when associated with a short duration of viral sup-
pression using interferon-based treatment, has a positive im-
pact on future clinical outcomes at 6 years and fibrosis regres-
sion [42]. Chronic inflammationmight be expected to increase
perfusion but is unknown in the context of advanced liver
disease. A recent MRI study showed reduced perfusion is
associated with progressive liver disease and linked to adverse
outcomes [29], and CT has shown worsening perfusion with
progressive fibrosis in HCV [43]. This is consistent with our
finding of a significant increase in liver perfusion with the
likely acute resolution of chronic necroinflammation after
DAA treatment in advanced liver disease caused by HCV.
A multimodal technique including MRI that captures how
the different aspects of liver composition, perfusion and blood
flow change over time could provide additional confidence for
clinical decision-making. In addition, robust non-invasive
tests that are specific to the liver would be valuable to drug
development for antifibrotic compounds as they can be repeat-
ed at multiple time points to evaluate drug efficacy. MRI has
the potential to be a key non-invasive tool to evaluate the
efficacy of interventions in chronic liver disease and stratify
patients according to the potential clinical outcomes.
In summary, for the first time, our MRI study has shown
that treatment of HCV with DAAs in patients with cirrhosis
leads to an acute reduction in liver T1, T2 and T2* and increase
in liver perfusion measured. The ability ofMRI to characterise
changes in the angio-architecture of patients with cirrhosis
after intervention at such short intervals will enhance our un-
derstanding of the progression/regression of chronic liver dis-
ease and potentially assist clinical decision-making. The sen-
sitivity of these MR measures should be exploited to
Fig. 4 Bulk flow to the liver in the (b) portal vein and (a) hepatic artery as
well as (d) superior mesenteric and (c) splenic artery flow shows no
significant changes between pre- and post-DAA therapies. e An increase
in liver perfusion of mean change 28.1 ± 19.7 ml/100 g/min is observed
following DAA therapy
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accelerate early phase of clinical development of novel
antifibrotic agents.
In future work, our intention is to use quantitative MRI
measures to observe the long-term effects of DAA therapy on
liver composition, perfusion and surrounding haemodynamics
to characterise the extent of fibrosis regression, vascular remod-
elling and reduction in portal hypertension that may occur after
DAA therapy. Furthermore, we aim to assess whether MRI
changes correspond to, or are predictive of, histological regres-
sion of fibrosis, as described in long-term studies with interfer-
on and ribavirin [10, 44, 45].
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